Search Results

You are looking at 61 - 70 of 211 items for :

  • Refine by Access: All x
Clear All
Full access

Vemurafenib Treatment of BRAF V600E-Mutated Malignant Peripheral Nerve Sheath Tumor

Henry G. Kaplan

left posterior neck tumor was 3 cm. During the third week of treatment, the patient experienced rapid onset of a macular erythematous rash that quickly grew to cover approximately 90% of her body. This was accompanied by daily fevers ranging from 102

Full access

Prevalence of Physical Problems Detected by the Distress Thermometer and Problem List in Patients With Myeloproliferative Disorders

Daniel C. McFarland, Kelly M. Shaffer, Heather Polizzi, John Mascarenhas, Marina Kremyanskaya, Jimmie Holland, and Ronald Hoffman

with MPNs experience a unique constellation of physical symptoms, such as pruritus, night sweats, bone and splenic pain, fatigue, and fevers. Symptom burden can be similar in severity to the experience of patients with metastatic cancer or acute myeloid

Full access

Novel Agents for the Treatment of Acute Myeloid Leukemia in the Older Patient

Maria R. Baer and Ivana Gojo

cytogenetic risk group. Thus, clofarabine shows encouraging results in older patients, including those with unfavorable karyotypes. However, the treatment is myelosuppressive, with most patients requiring hospitalization for neutropenic fever or infection

Full access

Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation

Smith Giri, Shadi Hamdeh, Vijaya Raj Bhatt, and James K. Schwarz

experienced disease control for 7 months with the combination of chemotherapy and sorafenib. Case Presentation A 65-year-old man presented to the emergency room who had experienced worsening pain in both calves during the past 2 to 3 weeks, fever and

Full access

Concurrent BRAF/MEK Inhibitors in BRAF V600–Mutant High-Grade Primary Brain Tumors

Karisa C. Schreck, Andrew Guajardo, Doris D.M. Lin, Charles G. Eberhart, and Stuart A. Grossman

dabrafenib at 150 mg twice daily and trametinib at 2 mg daily, with a Karnofsky performance status (KPS) of 50 and an ECOG performance status (PS) of 3. Treatment was complicated by fevers and a rash that responded to steroids. The steroids were titrated to

Full access

Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Lindsey Robert Baden, Sankar Swaminathan, Michael Angarone, Gayle Blouin, Bernard C. Camins, Corey Casper, Brenda Cooper, Erik R. Dubberke, Ashley Morris Engemann, Alison G. Freifeld, John N. Greene, James I. Ito, Daniel R. Kaul, Mark E. Lustberg, Jose G. Montoya, Ken Rolston, Gowri Satyanarayana, Brahm Segal, Susan K. Seo, Shmuel Shoham, Randy Taplitz, Jeffrey Topal, John W. Wilson, Karin G. Hoffmann, and Courtney Smith

development of symptoms that are suggestive of influenza (eg, high fever, coryza, myalgia, dry cough), especially during community outbreaks. Both the Infectious Diseases Society of America (2007) and CDC guidelines (2011) recommend antiviral treatment with

Full access

Treatment of Cancer-Associated Retinopathy With Rituximab

Irene Dy, Rangaswamy Chintapatla, Isabel Preeshagul, and Daniel Becker

-related autoimmune retinopathy and was referred to an oncologist for further evaluation. She had no detectable antiretinal antibodies. She was a nonsmoker with no significant past medical history. She denied weight loss, fever, abdominal pain, dysuria, vaginal

Full access

Growth Factors in Leukemia

Olga Frankfurt and Martin S. Tallman

. Crawford J Ozer H Stoller R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl J Med 1991 ; 325 : 164 – 170 . 7. Ohno R Tomonaga M Kobayashi T

Full access

Optimizing First-Line Therapy for Follicular Lymphoma: Is It Time for Chemotherapy-Free Approaches?

Richard I. Fisher

/chemotherapy arm experienced more neutropenia and fever; however, overall, treatment discontinuations were similar in both arms: 69% of patients on the R 2 arm and 71% of those on the rituximab/chemotherapy arm completed treatment. 13 Final data showed that R 2

Full access

Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion

Yong Li, Xian Chen, Yanchun Qu, Jia-Ming Fan, Yan Li, Hui Peng, Yaojie Zheng, Yihong Zhang, and Hai-Bo Zhang

Symptoms of disease are often restricted to the involved organ, and 15% to 30% of patients present with fever, malaise, microcytic anemia, weight loss, thrombocytosis, elevated erythrocyte sedimentation rate, or polyclonal hypergammaglobulinemia. 3 Surgery